Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.33 Million USD | 382.74% |
| 2022 | 1.69 Million USD | 1434.03% |
| 2021 | 110.59 Thousand USD | 142.73% |
| 2020 | 45.56 Thousand USD | 352.42% |
| 2019 | 10.07 Thousand USD | -82.05% |
| 2018 | 56.11 Thousand USD | 946.57% |
| 2017 | -6629.00 USD | 89.08% |
| 2016 | -60.73 Thousand USD | 84.14% |
| 2015 | -382.87 Thousand USD | -45.39% |
| 2014 | -263.33 Thousand USD | 44.56% |
| 2013 | -475 Thousand USD | -90.0% |
| 2012 | -250 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.3 Million USD | -0.27% |
| 2024 Q1 | 2.31 Million USD | -8.47% |
| 2023 Q3 | 1.99 Million USD | 1.92% |
| 2023 Q1 | 1.82 Million USD | 22.6% |
| 2023 Q2 | 1.95 Million USD | 6.82% |
| 2023 Q4 | 2.52 Million USD | 26.9% |
| 2023 FY | 8.19 Million USD | 382.74% |
| 2022 Q4 | 1.49 Million USD | 2124.73% |
| 2022 Q2 | 75.62 Thousand USD | 20.42% |
| 2022 FY | 1.69 Million USD | 1434.03% |
| 2022 Q1 | 62.8 Thousand USD | 163.54% |
| 2022 Q3 | 67.02 Thousand USD | -11.37% |
| 2021 Q3 | 30.87 Thousand USD | -10.15% |
| 2021 Q1 | 21.53 Thousand USD | 22.72% |
| 2021 Q4 | 23.82 Thousand USD | -22.81% |
| 2021 Q2 | 34.35 Thousand USD | 59.53% |
| 2021 FY | 110.59 Thousand USD | 142.73% |
| 2020 FY | 45.56 Thousand USD | 352.42% |
| 2020 Q4 | 17.55 Thousand USD | 62.35% |
| 2020 Q2 | 9984.00 USD | 38.3% |
| 2020 Q3 | 10.81 Thousand USD | 8.27% |
| 2020 Q1 | 7219.00 USD | 13.31% |
| 2019 FY | 10.07 Thousand USD | -82.05% |
| 2019 Q1 | 34.86 Thousand USD | 140.81% |
| 2019 Q2 | 1573.00 USD | -95.49% |
| 2019 Q3 | 2033.00 USD | 29.24% |
| 2019 Q4 | 6371.00 USD | 213.38% |
| 2018 FY | 56.11 Thousand USD | 946.57% |
| 2018 Q4 | 14.47 Thousand USD | -57.59% |
| 2018 Q3 | 34.13 Thousand USD | 118.56% |
| 2018 Q2 | 15.61 Thousand USD | 261.84% |
| 2018 Q1 | -9651.00 USD | -157.45% |
| 2017 Q4 | 16.8 Thousand USD | 200.0% |
| 2017 Q3 | -16.8 Thousand USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 FY | -6629.00 USD | 89.08% |
| 2016 Q4 | 34.06 Thousand USD | 459.26% |
| 2016 FY | -60.73 Thousand USD | 84.14% |
| 2016 Q3 | -9483.00 USD | -22.19% |
| 2016 Q2 | -7761.00 USD | 0.0% |
| 2016 Q1 | - USD | 100.0% |
| 2015 Q2 | -142.4 Thousand USD | -184.8% |
| 2015 Q3 | -64.98 Thousand USD | 54.36% |
| 2015 Q4 | -127.19 Thousand USD | -95.73% |
| 2015 FY | -382.87 Thousand USD | -45.39% |
| 2015 Q1 | -50 Thousand USD | 37.5% |
| 2014 Q3 | -30 Thousand USD | 57.14% |
| 2014 FY | -263.33 Thousand USD | 44.56% |
| 2014 Q2 | -70 Thousand USD | 16.0% |
| 2014 Q4 | -80 Thousand USD | -166.67% |
| 2014 Q1 | -83.33 Thousand USD | 16.67% |
| 2013 Q2 | -5655.00 USD | 97.74% |
| 2013 Q1 | -250 Thousand USD | -66.67% |
| 2013 Q4 | -100 Thousand USD | -100.0% |
| 2013 FY | -475 Thousand USD | -90.0% |
| 2013 Q3 | -50 Thousand USD | -784.17% |
| 2012 Q3 | -100 Thousand USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | -150 Thousand USD | -50.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | -250 Thousand USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Theratechnologies Inc. | 62.12 Million USD | 86.578% |
| Harrow Health, Inc. | 90.55 Million USD | 90.791% |
| Dynavax Technologies Corporation | 182.11 Million USD | 95.421% |
| Biofrontera Inc. | 16.62 Million USD | 49.846% |
| Cronos Group Inc. | 6.99 Million USD | -19.286% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -75.746% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 98.11% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2852.202% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -173.042% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 75.096% |
| Radius Health, Inc. | 307.71 Million USD | 97.29% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 17.253% |
| DURECT Corporation | 6.83 Million USD | -22.078% |
| ProPhase Labs, Inc. | 16.23 Million USD | 48.647% |
| Safety Shot Inc | -74.45 Thousand USD | 11299.983% |
| Phibro Animal Health Corporation | 312.48 Million USD | 97.331% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -1405.344% |
| Alvotech | -69.42 Million USD | 112.012% |
| Assertio Holdings, Inc. | 125.04 Million USD | 93.331% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.408% |
| Rockwell Medical, Inc. | 8.7 Million USD | 4.192% |
| Procaps Group S.A. | 239.56 Million USD | 96.519% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 98.063% |
| SCYNEXIS, Inc. | 124.51 Million USD | 93.303% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 84.723% |
| Viatris Inc. | 6.43 Billion USD | 99.87% |
| OptiNose, Inc. | 62.35 Million USD | 86.626% |
| SIGA Technologies, Inc. | 122.09 Million USD | 93.17% |
| Tilray Brands, Inc. | 223.35 Million USD | 96.266% |
| PetIQ, Inc. | 252.74 Million USD | 96.7% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 0.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.549% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -54.586% |
| Alimera Sciences, Inc. | 61.17 Million USD | 86.367% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 97.443% |
| Silver Spike Investment Corp. | 8.1 Million USD | -2.92% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 122536.808% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 97.308% |
| Journey Medical Corporation | 52.52 Million USD | 84.122% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -98.97% |
| Alpha Teknova, Inc. | 10.29 Million USD | 19.006% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -27.199% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 80.074% |
| PainReform Ltd. | -15 Thousand USD | 55694.473% |
| Cosmos Health Inc. | 4.34 Million USD | -91.724% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 69.247% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -540.489% |
| Embecta Corp. | 749.9 Million USD | 98.888% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 1218.469% |
| Talphera, Inc. | -4.89 Million USD | 270.361% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 98.299% |
| Incannex Healthcare Limited | 12 Thousand USD | -69393.092% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 445.998% |
| Shineco, Inc. | 882.16 Thousand USD | -845.304% |
| Procaps Group, S.A. | 239.56 Million USD | 96.519% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 97.269% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 71.971% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 98.825% |
| Alvotech | -69.42 Million USD | 112.012% |
| Hempacco Co., Inc. | -1.21 Million USD | 785.881% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 96.238% |
| Bright Green Corporation | -237.01 Thousand USD | 3618.4% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 88.587% |
| Kamada Ltd. | 52.59 Million USD | 84.144% |
| Indivior PLC | 907 Million USD | 99.081% |
| Evoke Pharma, Inc. | 4.97 Million USD | -67.495% |
| Flora Growth Corp. | 17.73 Million USD | 52.987% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 445.998% |
| Evolus, Inc. | 140.52 Million USD | 94.066% |
| HUTCHMED (China) Limited | 453.55 Million USD | 98.161% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 97.576% |
| Akanda Corp. | 111.44 Thousand USD | -7382.5% |